Ask AI
ProCE Banner Activity

CE / CME

Novel Therapeutic Approaches and Personalized Strategies for Managing Anemia in LR-MDS

Video

In this certified on-demand webcast, experts discuss novel therapeutic strategies and personalized treatment options for managing anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS), with a focus on the use of luspatercept and imetelstat, and emerging evidence from key trials such as COMMANDS, MEDALIST, and IMerge.

Physicians: Maximum of 1.25 AMA PRA Category 1 Credits

ABIM MOC: maximum of 1.25 Medical Knowledge MOC points

Released: July 15, 2025

Expiration: January 14, 2026

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Bristol Myers Squibb and Geron.

Bristol Myers Squibb

Geron

Target Audience

This activity has been designed to meet the educational needs of hematologists, hematologist-oncologists, and other healthcare professionals caring for patients with MDS.

Program Learning Goal

This activity aims to improve learners’ knowledge, confidence, and competence to optimize the care of patients with lower-risk MDS.

Learning Objectives

Upon completion of this activity, participants should be able to: 

  • Design individualized treatment plans for patients with LR-MDS, incorporating the latest clinical data, recent therapeutic approvals, updated WHO and ICC guidelines, and validated risk stratification tools to enhance diagnosis, prognosis, and management strategies

  • Establish comprehensive management protocols for anemia in the first-line setting for MDS patients, including tailored approaches for those not responding to erythropoiesis-stimulating agents (ESAs), to improve treatment efficacy and patient outcomes

  • Incorporate recent clinical trial evidence and treatment approvals into therapeutic decision-making for patients with very low–, low-, or intermediate-risk MDS, considering dosing frequency, dose escalation, and response durability to optimize care

  • Implement a multidisciplinary, evidence-based approach to managing adverse events associated with current and recently approved systemic therapies in LR-MDS, ensuring adequate dosing, monitoring, and timely intervention for AE mitigation

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Rami Komrokji, MD: consultant/advisor/speaker: Bristol Myers Squibb, Daiichi Sankyo, Geron, Jazz, PharmaEssentia, Rigel, Sevier, Sobi, Sumitomo; researcher: Keros.

Maximilian Stahl, MD: consultant/advisor/speaker: Bristol Myers Squibb, GlaxoSmithKline, Kura, Kymera, Novartis, Rigel, Sierra Oncology, Sobi, Syndax; medical safety monitoring board: Keros.

Amer Zeidan, MBBS, MHS: consultant/advisor/speaker/clinical trial committee: AbbVie, Akeso, Agios, Amgen, Astellas, BeiGene, BioCryst, Boehringer Ingelheim, Celgene/Bristol Myers Squibb, Chiesi/Cornerstone Biopharma, Daiichi Sankyo, Dr Reddy, Epizyme, FibroGen, Glycomimetics, Genentech, Gilead, Geron, GSK, Janssen, Jasper, Karyopharm, Keros, Kura, Kyowa Kirin, Notable, Novartis, Orum, Otsuka, Pfizer, Regeneron, Rigel, Schrodinger, Seattle Genetics, Servier, Shattuck Labs, Syndax, Syros, Takeda, Treadwell, Taiho, Vincerx, Zentalis.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from July 15, 2025, through January 14, 2026:

  1. Login or Sign Up for an account by clicking at the top of this page.

  2. Read the target audience, learning objectives, and faculty disclosures.

  3. View and study the content in its entirety.

  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification

https://omni-channel-2022-assets-production.s3.amazonaws.com/editorupload/67167f3d10da3.png

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For ABIM MOC points, your information will be shared with the ABIM through CCO's Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

By sharing your Diplomate Board ID # and DOB, you are giving Clinical Care Options, LLC permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).

CME Passport

https://omni-channel-2022-assets-production.s3.amazonaws.com/editorupload/662be69741e7b.png

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.